|Articles|April 15, 2004

FDA expedites review of kidney cancer drug

The FDA has added BAY 43-9006, an investigational treatment for metastatic renal cell carcinoma, to its fast track program.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME